RxDoctor Payments Data

Emalee Justice, PA

Physician Assistant · Knoxville, TNNPI 1023899051

Payments from drug & device makers

$2,284in general payments, 2019–2025

Across 104 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$419
  • Merck$213
  • GSK$212
  • United Therapeutics Corporation$205
  • Sanofi$179
  • Grifols USA, LLC$171
  • plus $885 from 16 others

What the payments were for

  • Food & beverage$2,20597%
  • Education$793%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,284 in reported general payments places this provider in the 80th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$13,827
Medicare patients
103
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$25,182
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$15,609
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$15,505
Breo ElliptaFluticasone/Vilanterol14$10,535
Albuterol Sulfate HfaAlbuterol Sulfate99$4,317
SymbicortBudesonide/Formoterol Fumarate18$3,959
Roflumilast11$598
Omeprazole22$375
Fluticasone Propionate12$301
Montelukast Sodium13$188
Azithromycin16$109
Prednisone43$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$212$35,71735 claims
AstraZenecaBreztri Aerosphere, Symbicort$419$19,56837 claims
Boehringer IngelheimStiolto Respimat$45$15,50533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →